Added to YB: 2026-10-07
Pitch date: 2026-10-02
468530.KQ [neutral]
Proteina Co., Ltd.
-35.33%
current return
Author Info
No bio for this author
Company Info
Proteina Co., Ltd. develops protein-protein interaction profiling technology. The company offers technology that confirms the real-time activation of cancer signal pathways by directly seeing the relevant proteins, predicts the efficacy of drugs, and enables doctors to select which inhibitor to prescribe by confirming which bypass signal pathways are inducing resistance.
Market Cap
N/A
Pitch Price
KRW 54.2K
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
N/A
EV/Sales
N/A
Sector
Biotechnology
Category
growth
The U.S. AI-Biotech Rally: Why Proteina, GC Genome, and ST Pharm Need Separate Cases in Korea - Proteina Co., Ltd.
468530.KQ (monitor): Proteina’s SPID platform validates AI-designed antibodies at the single-molecule level, supported by collaborations with Twist and Samsung Bioepis and a plan to expand monthly capacity from 40,000 to 1 million interactions by 2028. Yet no committed orders or sales schedules are disclosed; H1 2026 revenue fell 74.4% to KRW520M, the operating loss was KRW8.67B, and the KRW569.7B market cap equaled ~193x 2025 revenue. Paid contracts and repeat orders are the next evidence.
Read full article (2 min)